Advanced search
Publication Cover
Renal Failure Volume 37, 2015 - Issue 1
Submit an article Journal homepage
1,846
Views
2
CrossRef citations to date
0
Altmetric
Clinical Study

The optimal timing of hemoperfusion component in combined hemodialysis–hemoperfusion treatment for uremic toxins removal

Jiangtao LiDepartment of Nephrology, Tongji Hospital, Tongji University, Shanghai, China
,
Daming LiDepartment of Nephrology, Tongji Hospital, Tongji University, Shanghai, China
,
Yan XuDepartment of Nephrology, Tongji Hospital, Tongji University, Shanghai, China
,
Aili WangDepartment of Nephrology, Tongji Hospital, Tongji University, Shanghai, China
,
Chen XuDepartment of Nephrology, Tongji Hospital, Tongji University, Shanghai, China
&
Chen YuDepartment of Nephrology, Tongji Hospital, Tongji University, Shanghai, ChinaCorrespondence[email protected]
Pages 103-107 | Received 22 Jun 2014, Accepted 28 Sep 2014, Published online: 25 Nov 2014

References

  • Hörl WH. The clinical consequences of secondary hyperparathyroidism: Focus on clinical outcomes. Nephrol Dial Transplant. 2004;19(Suppl 5):2–8
  • De Francisco AM, Cassidy MJ, Owen JP, et al. Ectopic calcification. The role of parathyroid hormone. Proc Eur Dial Transplant Assoc Eur Ren Assoc. 1985;21:888–894
  • Dember LM, Jaber BL. Dialysis-related amyloidosis: Late finding or hidden epidemic? Semin Dial. 2006;19(2):105–109
  • Schiffl H. Carpal tunnel syndrome in patients on intermittent hemodialysis. Blood Purif. 2012;34(3–4):332
  • Herbelin A, Nguyen AT, Zingraff J, et al. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. Kidney Int. 1990;37(1):116–125
  • Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins classification concentration, and interindividual variability. Kidney Int. 2003;63(5):1934–1943
  • Schömig M, Eisenhardt A, Ritz E. The microinflammatory state of uremia. Blood Purif. 2000;18(4):327–332
  • Zeceali C, Tripepi G, Mallamaci F. Dissecting inflammation in ESRD: Do cytokines and C-reactive protein have a complementary prognostic value for mortality in patient. Am Soc Nephol. 2006;17(12 Suppl 3):169–173
  • USRDS. Excerpts from the United States renal data system 1998 annual data report. Patient mortality and survival. Am J Kidney Dis. 1998;32(2 Suppl 1):69–80
  • Henderson LW, Colton CK, Ford CA, et al. Kinetics of hemodiafiltration. II. Clinical characterization of a new blood cleansing modality. J Lab Clin Med. 1975;85(3):372–391
  • Leber HW, Wizemann V, Goubeaud G, et al. Hemodiafiltration: A new alternative to hemofiltration and conventional hemodialysis. Artif Organs. 1978;2(2):150–153
  • Trznadel K, walasek L, Kidawa Z, et al. Comparative studies on the effect of hemoperfusion and hemodialysis on the elimination of some uremic toxins. Clin Nephrol. 1978;10:229–232
  • Bonomini V, Stefoni S, Casciani CU, et al. Multicentric experience with combined hemodialysis/hemoperfusion in chronic uremia. Contrib Nephol. 1982;29:133–142
  • Stefoni S, Coli L, Feliciangli G, et al. Regular hemoperfusion in regular dialysis treatment. A long-term study. Int J Artif Organs. 1980;3(6):348–353
  • Chen SJ, Jiang GR, Shan JP, et al. Combination of maintenance hemodialysis with hemoperfusion: A safe and effective model of artificial kidney. Int J Artif Organs. 2011;34(4):339–347
  • Li-Ying Miao, Bin Zhu, Xiao-Zhou He, et al. Effects of three blood purification methods on serum fibroblast growth factor-23 clearance in patients with hyperphosphatemia undergoing maintenance hemodialysis. Exp Ther Med. 2014;7(4):947–952
  • NKFI. K/DOQI Clinical Practice Guidelines for Hemodialysis Adequacy: Update 2000. Am J Kidney Dis. 2001;37(1 Suppl 1):S7–S64
  • Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int. 2003;63:1934–1943
  • Bergstrom J, Wehle B. No change in corrected beta2-microgobulin concentration after cuprophane hemodialysis. Lancet. 1987;1:628–629
  • Winchester JF, Ratcliffe JG, Carlyle E, et al. Solute, amino acid, and hormone changes with coated charcoal hemoperfusion in uremia. Kidney Int. 1978;14(1):74–81
  • Bonomini V, Stefoni S, Feliciangeli G, et al. Shortened treatment time by combined hemodialysis and hemoperfusion. Contr Nephrol. 1985;44:57–64
  • Winchester JF. Sorbent hemoperfusion in end-stage renal disease: An in-depth review. Adv Renal Replace Ther. 2002;9(1):19–25
  • Chnediatz D, Putz-Bankuti C, Ribitsch W, et al. Correction of plasma concentrations for effects of hemoconcentration or hemodilution. ASAIO J. 2012;58(2):160–162
  • Tae Yamamoto, Marcelo M. Nascimento, Shirley Y. Hayashi, et al. Changes in circulating biomarkers during a single hemodialysis session. Hemodialysis Intern. 2013;17:59–66

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.